Skip to nav Skip to content

Clinical Trial Search

305 Clinical Trials Found

Clinical Trial 20963

A Phase 2 Study of Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)
Disease Site: Myeloid and Monocytic Leukemia
PI: Kuykendall, Andrew

Clinical Trial 20871

A Phase 3, Open-label, Randomized, Multicenter Study of Ravulizumab in Adult and Adolescent Participants who have Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplant (HSCT)
Disease Site: Unknown Sites
PI: Nishihori, Taiga

Clinical Trial 20415

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Safety And Efficacy Of Polatuzumab Vedotin In Combination With RituximabI Plus Gemcitabine Plus Oxaliplatin (R-Gemox) Versus R-Gemox Alone In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Disease Site: Myeloid and Monocytic Leukemia
PI: Sandoval-Sus, Jose

Clinical Trial 20641

A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma
Disease Site: Melanoma, skin
PI: Eroglu, Zeynep

Clinical Trial 20831

A Phase 1b/3 Double-Blind, Randomized,Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
PI: Gaballa, Sameh

Clinical Trial 21143

Disease Site: Mycosis Fungoides
PI: Sokol, Lubomir

Clinical Trial 21341

A Phase II Study of Cemiplimab plus Ziv-Aflibercept for Subjects with Metastatic Uveal Melanoma
Disease Site: Eye and Orbit
PI: Tarhini, Ahmad

Clinical Trial 21626

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 21707

A Proof of Concept Study of TBio-4101 (an Autologous selected and expanded tumor infiltrating lymphocyte [TIL] therapy) Using Short-Term Cultured, Selected Autologous TIL following a Lymphodepleting Chemotherapy Regimen and Followed by IL-2 for Patients with Relapsed or Refractory Solid Tumors (Phase 1)
Disease Site: Colon, Melanoma, skin, Rectum
PI: Sarnaik, Amod

Clinical Trial 21887

A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes
Disease Site: Leukemia, other
PI: Padron, Eric

Clinical Trial 22095

A Phase 2 study of Canakinumab in patients with Myelofibrosis
Disease Site: Myeloid and Monocytic Leukemia
PI: Kuykendall, Andrew

Clinical Trial 22100

Disease Site: Multiple Myeloma
PI: Grajales-Cruz, Ariel